Array BioPharma To Present at the Jefferies 2018 Global Healthcare Conference
Get Alerts ARRY Hot Sheet
Join SI Premium – FREE
BOULDER, Colo., May 30, 2018 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will speak at the Jefferies 2018 Global Healthcare Conference in New York. The public is welcome to participate in the conference through a webcast on the Array BioPharma website.
|
Event: |
Jefferies 2018 Global Healthcare Conference |
|
Presenter: |
Ron Squarer, Chief Executive Officer, Array BioPharma |
|
Date: |
Wednesday, June 6, 2018 |
|
Time: |
2 p.m. Eastern Time |
|
Webcast: |
About Array BioPharma Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer and other conditions. Ten registration studies are currently advancing related to eight Array-owned or partnered drugs: encorafenib (LGX818), binimetinib (MEK162), ARRY-797, selumetinib (partnered with AstraZeneca), danoprevir (partnered with Roche), ipatasertib (partnered with Genentech), larotrectinib (partnered with Loxo Oncology) and tucatinib (partnered with Seattle Genetics). For more information on Array, please go to www.arraybiopharma.com.
CONTACT: Andrea N. Flynn, Ph.D. Senior Director, Investor Relations & Corporate Communications (303) 381-6600 [email protected]

View original content with multimedia:http://www.prnewswire.com/news-releases/array-biopharma-to-present-at-the-jefferies-2018-global-healthcare-conference-300655974.html
SOURCE Array BioPharma
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Miss Palestine Announces Its First National Competition in Recent History
- ChronoTech AI Inc. Launches Intelligent Robotics Platform
- Cognizant and Benchling Selected as Partners to Accelerate Kyowa Kirin's R&D
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Jefferies & CoSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share